DE69839846D1 - Bestimmung der vorhandenen mengen an cyclin-abhängr bei krebspatienten - Google Patents

Bestimmung der vorhandenen mengen an cyclin-abhängr bei krebspatienten

Info

Publication number
DE69839846D1
DE69839846D1 DE69839846T DE69839846T DE69839846D1 DE 69839846 D1 DE69839846 D1 DE 69839846D1 DE 69839846 T DE69839846 T DE 69839846T DE 69839846 T DE69839846 T DE 69839846T DE 69839846 D1 DE69839846 D1 DE 69839846D1
Authority
DE
Germany
Prior art keywords
determination
cancer patients
cyclin
depending
existing amounts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839846T
Other languages
English (en)
Inventor
Antonio Giordano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Application granted granted Critical
Publication of DE69839846D1 publication Critical patent/DE69839846D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
DE69839846T 1997-05-15 1998-05-14 Bestimmung der vorhandenen mengen an cyclin-abhängr bei krebspatienten Expired - Lifetime DE69839846D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4652997P 1997-05-15 1997-05-15
PCT/US1998/009788 WO1998051821A1 (en) 1997-05-15 1998-05-14 Determination of cyclin-dependent kinase inhibitor p27 levels as a prognostic factor in cancer patients

Publications (1)

Publication Number Publication Date
DE69839846D1 true DE69839846D1 (de) 2008-09-18

Family

ID=21943928

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839846T Expired - Lifetime DE69839846D1 (de) 1997-05-15 1998-05-14 Bestimmung der vorhandenen mengen an cyclin-abhängr bei krebspatienten

Country Status (7)

Country Link
US (1) US6180333B1 (de)
EP (1) EP1023459B1 (de)
JP (1) JP2001525673A (de)
AT (1) ATE403744T1 (de)
CA (1) CA2289942C (de)
DE (1) DE69839846D1 (de)
WO (1) WO1998051821A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482506B2 (en) * 2001-03-26 2009-01-27 University Of South Florida Ras p27 mouse models and uses thereof
EP3115470B1 (de) * 2002-03-13 2018-07-18 Genomic Health, Inc. Genexpressionsprofilierung in biopsierten tumorgeweben
US9169516B2 (en) * 2003-01-24 2015-10-27 University Of Utah Research Foundation Methods of predicting mortality risk by determining telomere length
WO2010088457A2 (en) * 2009-01-29 2010-08-05 H. Lee Moffitt Cancer And Research Institute, Inc. Methods for inducing tumor regression, inhibiting tumor growth, and inducing apoptosis in breast tumors with geranylgeranyltransferase i inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688665A (en) * 1994-01-07 1997-11-18 Fred Hutchinson Cancer Research Center Isolated nucleic acid molecules encoding the p27 KIP-1 protein
WO1999004238A2 (en) * 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders

Also Published As

Publication number Publication date
EP1023459A1 (de) 2000-08-02
US6180333B1 (en) 2001-01-30
WO1998051821A1 (en) 1998-11-19
CA2289942A1 (en) 1998-11-19
EP1023459B1 (de) 2008-08-06
JP2001525673A (ja) 2001-12-11
ATE403744T1 (de) 2008-08-15
EP1023459A4 (de) 2002-01-09
CA2289942C (en) 2009-05-05

Similar Documents

Publication Publication Date Title
ATE194660T1 (de) Veraendertes gen bei menschlichem colorektalem- krebs
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
DE69830927D1 (de) Bewertung von humaner papillomvirus verwandter krankheit
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
AU6473598A (en) Method for determining the presence of mutated brca protein
NO931635L (no) Fremgangsmaate for fremstilling av kinazolin-derivater
AU4085097A (en) Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
ATE238800T1 (de) Verwendung von squalamin zur herstellung eines arzneimittels zur inhibierung von nhe
DE69907153T2 (de) Krebsbehandlung
ATE273386T1 (de) Menschliches cyclin e
MX9708401A (es) Genes reguladores de la cromatina.
AU7868300A (en) Prostate cancer marker proteins
IL146125A0 (en) Novel quinones as disease therapies
EP1090294A4 (de) Verfahren um die anwesenheit von krebs in einer probe zu bestimmen durch nachweis der expression eines ssx-gens und peptiden, die von ssx oder ny-eso-1 abgeleitet sind
EP0163303A3 (de) Menschliche monoklonale Antikörper gegen Zelloberflächen- oder Innenzellantigene
DE69839846D1 (de) Bestimmung der vorhandenen mengen an cyclin-abhängr bei krebspatienten
ES473474A1 (es) Procedimiento para descubrir sustancias cancerigenas y subs-tancias anticancerosas
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
BR0012301A (pt) Inibidores de crescimento de células epiteliais
ATE256682T1 (de) Sigma-2 rezeptoren als biomarkierer der tumorzellenproliferation
ATE237697T1 (de) Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit
SE9702599D0 (sv) Provtagningsinstrument för undersökning av tumörer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition